Veno Occlusive Disease or VOD, is a condition in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments, that are given prior to stem cell transplantation. Severe VOD is the most extreme form of VOD and is associated with multiple-organ failure and high rates of morbidity and mortality.
Get More Details
Defibrotide is Gentium’s most advanced product candidate. Two pivotal Phase II/III clinical trials with defibrotide for the treatment and prevention of VOD have been completed, a Phase III trial for treatment of severe VOD in the U.S., Canada and Israel and Phase II/III pediatric trial in Europe for the prevention of VOD.
Product Pipeline
Gentium S.p.A. - P.IVA n. 02098100130